A phase 2 study of MKC-1 administered twice daily for 14 consecutive days every 4 weeks in patients with recurrent or resistant epithelial ovarian cancer or advanced endometrial cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2014
At a glance
- Drugs MKC 1 (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors CASI Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 19 Jan 2012 Actual patient number (44) added as reported by ClinicalTrials.gov.
- 19 Jan 2012 Actual end date (1 Jan 2012 ) added as reported by ClinicalTrials.gov.